Home > Boards > US Listed > Medical - Drugs > AstraZeneca PLC (AZN)

AZN- TD Ameritrade won’t let me copy, but

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biotech_researcher Member Profile
 
Followed By 68
Posts 11,886
Boards Moderated 0
Alias Born 07/25/08
160x600 placeholder
NeoTX Closes $45 Million Series C Financing GlobeNewswire Inc. - 2/19/2020 3:00:10 AM
AstraZeneca 4Q Core Operating Profit Tumbled, Expects Growth in 2020 Dow Jones News - 2/14/2020 3:03:00 AM
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney D... GlobeNewswire Inc. - 2/11/2020 5:00:10 PM
Educational Lung Cancer Event Coming to The Villages to Raise Awareness of the State’s High Rate of Lung Cancer Business Wire - 1/30/2020 9:00:00 AM
BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke Business Wire - 1/27/2020 7:00:00 AM
AstraZeneca: Enhertu Phase 2 Trial Meets Primary Endpoint Dow Jones News - 1/27/2020 2:58:00 AM
AstraZeneca's Brilinta Met Primary Endpoint in Phase Three Stroke Trial Dow Jones News - 1/27/2020 2:54:00 AM
AstraZeneca to Recover Global Rights to Brazikumab From Allergan Dow Jones News - 1/27/2020 2:48:00 AM
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep PR Newswire (US) - 1/27/2020 1:15:00 AM
AstraZeneca Pledges $1 Billion to Cut CO2 Emissions Dow Jones News - 1/22/2020 5:38:00 AM
Myriad Submits sPMA for BRACAnalysis CDx Test Dow Jones News - 1/21/2020 7:58:00 AM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Form of Prostate Cancer Dow Jones News - 1/21/2020 7:43:00 AM
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prost... GlobeNewswire Inc. - 1/21/2020 7:05:10 AM
AstraZeneca: FDA Gives Orphan Drug Status to Two Liver Cancer Drugs Dow Jones News - 1/20/2020 2:48:00 AM
AstraZeneca's Prostate Cancer Supplemental Drug Gets U.S. Approval Dow Jones News - 1/20/2020 2:46:00 AM
My Green Lab Working with AstraZeneca to Implement Green Labs Program Dow Jones News - 1/14/2020 12:03:00 PM
AstraZeneca Faces $100 Million Impairment After Disappointing Epanova Data -- Update Dow Jones News - 1/13/2020 8:22:00 AM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Advanced Ovarian Cancer Dow Jones News - 1/13/2020 7:43:00 AM
AstraZeneca to Discontinue Epanova Trial Following Disappointing Data Dow Jones News - 1/13/2020 2:37:00 AM
FDA to Review Extending Uses for AstraZeneca-Controlled Drug Dow Jones News - 1/6/2020 7:51:00 AM
FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction Business Wire - 1/6/2020 7:00:00 AM
AstraZeneca, Merck Get FDA OK for Lynparza in Pancreatic Cancer Indication Dow Jones News - 12/30/2019 7:49:00 AM
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germlin... GlobeNewswire Inc. - 12/30/2019 7:05:10 AM
LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Can... Business Wire - 12/30/2019 6:55:00 AM
FDA Approves AstraZeneca's Lynparza for Pancreatic Cancer Dow Jones News - 12/30/2019 2:42:00 AM
biotech_researcher   Friday, 11/09/18 10:52:48 AM
Re: None
Post # of 149 

AZN- TD Ameritrade won’t let me copy, but the jest:

“Fat dividends that may be cut.”

AZN: dividend was $2.80 in 2014, now $1.37 (since 2016). 2018 earnings projection is $1.65, implies a 83% payout.

Too high of a payout for me....


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist